MEX-CD1
Cross-source consensus on MEX-CD1 from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Evidence quality
Where it comes from
Highlighted claims
- MEX-CD1 is a chelating polymer made from reacetylated chitosan functionalised by DOTAGA ligands. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
- MEX-CD1 has an approximately 300 kDa molecular weight that prevents crossing of the dialysis membrane. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
- MEX-CD1 is added to dialysate so that it remains confined to the dialysis circuit and avoids systemic exposure. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
- Preclinical studies found improved iron removal with MEX-CD1 at dialysate concentrations about twice those planned for the trial. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
- MEX-CD1 is described as continuously enhancing the iron extraction gradient without saturation. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p